AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer.
Show original
This move marks a critical step for the company in advancing the clinical development of this immunotherapy for this hard-to-treat cancer.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Musk appears in court to face market manipulation lawsuit during Twitter acquisition
BlockBeats•2026/03/04 23:59
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$72,647.24
+6.35%
Ethereum
ETH
$2,124.93
+7.13%
Tether USDt
USDT
$1
+0.01%
BNB
BNB
$657.71
+3.73%
XRP
XRP
$1.43
+5.08%
USDC
USDC
$0.9997
-0.02%
Solana
SOL
$90.93
+4.24%
TRON
TRX
$0.2871
+2.35%
Dogecoin
DOGE
$0.09913
+10.02%
Cardano
ADA
$0.2762
+4.96%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now